European Heart Journal Advance Access originally published online on September 26, 2008
European Heart Journal 2009 30(8):900-907; doi:10.1093/eurheartj/ehn417
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study
1 Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Canada
2 Academic Medical Center, Amsterdam, The Netherlands
3 Department of Cardiology, the University and the Royal Infirmary of Edinburgh, Edinburgh, UK
4 Dante Pazzanese Institute of Cardiology, Sao Paolo, Brazil
5 Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
6 GPR Clinikum Russelsheim, Russelsheim, Germany
Received 25 February 2008; revised 22 August 2008; accepted 28 August 2008; online publish-ahead-of-print 26 September 2008.
* Corresponding author: McMaster University and Population Health Research Institute, Hamilton Health Sciences, McMaster Clinic Room 630, 237 Barton St. East, Hamilton, ON, Canada L8L 2X2. Tel: +1 905 524 2712, Fax: +1 905 523 8352, Email: jollyss{at}mcmaster.ca
See page 882 for the editorial comment on this article (doi:10.1093/eurheartj/ehp105)
Aims: In the setting of percutaneous coronary intervention (PCI), due to a paucity of data, the optimal dose of aspirin is uncertain. We evaluated the safety of different doses of aspirin after PCI.
Methods and results: In the PCI-CURE study, 2658 patients with acute coronary syndromes undergoing PCI were stratified into three aspirin dose groups 
200 mg (high, n = 1064), 101–199 mg (moderate, n = 538), and 
100 mg (low, n = 1056). For efficacy, the moderate- (7.4%) and high-dose groups (8.6%) had similar rates of cardiovascular death, myocardial infarction, or stroke compared with the low-dose group (7.1%). For safety, major bleeding was increased with high-dose aspirin [3.9, 1.5, and 1.9% in the high-, moderate-, and low-dose groups; hazard ratio (HR) of high vs. low dose 2.05 (95% CI 1.20–3.50, P = 0.009]. The net adverse clinical events (death, MI, stroke, major bleeding) favoured low-over high-dose aspirin (8.4 vs. 11.0%, HR 1.31, 95% CI 1.00–1.73 P = 0.056).
Conclusion: In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance.
Key Words: Aspirin • Percutaneous coronary transluminal angioplasty • Myocardial infarction • Haemorrhage
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Aspirin following PCI: too much of a good thing?
- Steven R. Steinhubl and Peter B. Berger
EHJ 2009 30: 882-884.[Extract] [FREE Full Text] - Managing myocardial infarction in the elderly: time to bury inappropriate concerns instead
- Anthony H. Gershlick
EHJ 2009 30: 887-889.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  D. R. Holmes Jr, D. J. Kereiakes, N. S. Kleiman, D. J. Moliterno, G. Patti, and C. L. Grines Combining Antiplatelet and Anticoagulant Therapies. J. Am. Coll. Cardiol., July 7, 2009; 54(2): 95 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl and P. B. Berger Aspirin following PCI: too much of a good thing? Eur. Heart J., April 2, 2009; 30(8): 882 - 884. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Mehta Aspirin for Prevention and Treatment of Cardiovascular Disease Ann Intern Med, March 17, 2009; 150(6): 414 - 416. [Full Text] [PDF]
|
|